Key Points
- SVP Chan Henry Lee sold 664 shares on Jan. 7 at $331.76 each for $220,288.64, and had earlier sales of 332 shares (Dec. 11) and 996 shares (Nov. 12), representing repeated insider selling totaling about $675,962.
- BeOne shares opened at $337.89 (up ~5.5%), the stock has a market cap of $37.05 billion and a high P/E of 662.53, and analysts hold a consensus "Moderate Buy" with an average target of $367.36 (12 Buy, 1 Hold, 1 Sell).
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 664 shares of the company's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $331.76, for a total transaction of $220,288.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Chan Henry Lee also recently made the following trade(s):
- On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $325.00, for a total transaction of $107,900.00.
- On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32.
BeOne Medicines Trading Up 5.5%
BeOne Medicines stock opened at $337.89 on Friday. The stock has a 50-day simple moving average of $327.96 and a 200 day simple moving average of $313.24. The stock has a market capitalization of $37.05 billion, a P/E ratio of 662.53 and a beta of 0.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $174.74 and a 52 week high of $385.22.
Hedge Funds Weigh In On BeOne Medicines
A number of hedge funds have recently added to or reduced their stakes in the stock. Anchor Investment Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd bought a new stake in BeOne Medicines during the second quarter worth about $28,000. Daiwa Securities Group Inc. bought a new stake in BeOne Medicines during the second quarter worth about $35,000. Farther Finance Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter valued at about $39,000. Finally, Signaturefd LLC acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at approximately $49,000. Institutional investors own 48.55% of the company's stock.
Analysts Set New Price Targets
Several research firms have commented on ONC. Barclays started coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price objective on the stock. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Friday, October 3rd. Morgan Stanley restated an "overweight" rating and set a $405.00 price objective on shares of BeOne Medicines in a report on Thursday. Zacks Research lowered BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 28th. Finally, Citigroup lifted their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a "buy" rating in a report on Monday, November 10th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $367.36.
View Our Latest Stock Report on ONC
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
